Allogene Therapeutics (ALLO) Change in Acquisitions & Divestments (2018 - 2026)

Allogene Therapeutics has reported Change in Acquisitions & Divestments for 9 years, with the latest figure at $72.1 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 27.64% year-over-year to $72.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.6 million (up 137.74% YoY) and the FY2024 annual result came in at $5.4 million, down 99.1% from the prior year.
• Change in Acquisitions & Divestments grew to $72.1 million in Q1 2026 per ALLO's latest filing, from -$110.3 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $455.8 million in Q3 2023 and troughed at -$215.1 million in Q3 2024.
• A 5-year average of $79.6 million and a median of $72.1 million in 2026 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2024: Change in Acquisitions & Divestments slumped 214.84% in 2022, then surged 1736.6% in 2024.
• Over 5 years, Change in Acquisitions & Divestments stood at $359.5 million in 2022, then slumped by 62.07% to $136.3 million in 2023, then sank by 257.76% to -$215.1 million in 2024, then jumped by 48.72% to -$110.3 million in 2025, then soared by 165.38% to $72.1 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $72.1 million, -$110.3 million, and $53.8 million for Q1 2026, Q3 2025, and Q2 2025 respectively.